BIM
CSTL icon

Bogle Investment Management’s Castle Biosciences CSTL Stock Holding History

Bogle Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,100
Closed -$417K – 174
2020
Q3 		$417K Buy
+8,100
New +$360K 0.12% 170
2020
Q2 		– Sell
-29,603
Closed -$882K – 335
2020
Q1 		$882K Buy
29,603
+2,343
+9% +$70.7K 0.09% 173
2019
Q4 		$937K Buy
+27,260
New +$667K 0.09% 170

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bogle Investment Management's CSTL Position: Q4 2020 in Review

Bogle Investment Management sold out of Castle Biosciences (CSTL) in Q4 2020, closing a stake of 8,100 shares — an estimated $417K sold.

Bogle Investment Management first reported a position in CSTL in Q4 2019 and held it in 3 quarters. The position peaked at $937K in Q4 2019. 163 funds tracked by Wall St. Rank hold CSTL as of Q4 2020.

  • Bogle Investment Management reported no remaining Castle Biosciences position as of Q4 2020 after selling out during the quarter.
  • Bogle Investment Management sold 8,100 Castle Biosciences shares in Q4 2020, an estimated $417K.
  • Bogle Investment Management first reported a position in Castle Biosciences in Q4 2019 and held it in 3 quarters.
  • Bogle Investment Management's Castle Biosciences position peaked at $937K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2020.

Based on Bogle Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.